EBC MAIN STUD

Resolute Onyx™ is the only DES with randomised data supporting provisional and dual-stent strategies in Left Main Bifurcation PCI


Bifurcation PCIs, including the left main (LM), are prevalent and complex

- More than 80% of LM disease involves a bifurcation¹
- LM PCI presents challenges including wider bifurcation angles, large side branches, and additional calcification and fibrosis²
- Stent optimisation in the main branch, without compromising the side branch is required³
- The optimal treatment strategy for true left main bifurcations remains a highly debated topic

EBC Main Study Overview

- First randomised trial based on EBC Consensus, comparing the provisional to a planned dualstent strategy in LM bifurcation PCI
- 467 patients with true left main bifurcation disease enrolled in Europe
- Resolute Onyx DES was chosen because of its 4.5 and 5.0 mm diameters, which now expand to 6.0 mm[†]

Resolute Onyx[™] DES demonstrated excellent outcomes at one year²



- Primary endpoint (death, MI, TLR) showed numerically fewer serious adverse events in the provisional arm (14.7%) vs. dual-stent arm (17.7%)
- Provisional arm showed significantly shorter procedure duration and fluoroscopy time



RESOLUTE ONYX DES IS OPTIMISED FOR ...

Left Main Bifurcation PCI








- Expand to 6.0 mm[†] for optimal deployment with even scaffolding⁴
- Provide the sustained radial strength needed to handle the left main artery's elasticity⁴





Synergy^{™*} Megatron DES' post-dilatation at 6.0 mm diameters causes the struts to straighten as they approach their expansion limit.


Greater Radial Strength than Synergy Megatron DES at Maximum Expansion⁴



Bifurcation PCI


Single-wire design increases flexibility and conformability

to achieve optimal strut apposition.⁴



- Round struts create a smooth passage when accessing the side branch and lower the propensity to catch.⁴
- Platinum iridium core increases visibility for accurate stent placement without compromising strut thickness.4

Cobalt alloy shell



Cross Section of Resolute Onyx DES

Platinum iridium core

C € 2797

- *Third-party brands are trademarks of their respective owners.
- $^{\dagger}\text{Resolute}$ Onyx DES received CE and FDA approval for increased expansion in 2020.
- ¹ Rab T, et al. JACC Cardiovasc Interv. 2017;10:849-865.
- ² Hildick-Smith D, et al. Eur Heart J. Published online May 18, 2021.
- ³ Gwon, Hyeon-Cheol. *Korean Circ J.* 2018;48:481-491.
- ⁴ Data on file at Medtronic.



Medtronic

Europe Medtronic Intl. Trading SARL Tel: 41.21.802.7000 Asia Pacific Medtronic Intl. Ltd. Tel: 65.6436.5000 Latin America Medtronic Tel: 786.709.4200

medtronic.com

See more at **medtronic.com/bifurcation** where you can explore five step-by-step bifurcation techniques captured with endoscopic imaging inside an isolated, reanimated, beating porcine heart.

UC202201496 ML @2021 Medtronic. All rights reserved. Medtronic and the Medtronic logo are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Resolute Onyx $^{\rm m}$ coronary stent and the 0.25 mm expansion has been approved. Not for distribution in the U.S., Japan, France, Canada, or Australia. 08/2021